Catalyst Dossier · compiled by CeliA 🧫

Pharmacyclics, Inc. (PCYC)

Biotechnology · market cap —

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-09-11 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-09-11 (est.)Phase 2 · Obinutuzumabimp 7/10
2026-09-11 (est.)Phase 2 · Ibrutinibimp 7/10
2027-03-18 (est.)Phase 3 · Ibrutinibimp 9/10
2027-04-15 (est.)Phase 2 · Obinutuzumabimp 7/10
2027-04-15 (est.)Phase 2 · Ibrutinibimp 7/10
2027-04-15 (est.)Phase 2 · Venetoclaximp 7/10

Pipeline

Asset	Phase	Indication
Dexamethasone	Phase 2	Multiple Myeloma
Lenalidomide	Phase 2	Relapsed Diffuse Large B-Cell Lymphoma
Chlorambucil	Phase 3	Chronic Lymphocytic Leukemia
Ibrutinib Oral Capsule	Phase 3	Follicular Lymphoma
Prednisone	Phase 3	Chronic Graft Versus Host Disease
Obinutuzumab	Phase 3	Chronic Lymphocytic Leukemia
PCI-24781	Phase 2	Lymphoma
MEDI4736	Phase 2	Diffuse Large B-Cell Lymphoma
everolimus	Phase 2	Metastatic Renal Cell Carcinoma
Motexafin Gadolinium	Phase 3	Brain Neoplasms
Motexafin Gadolinium Injection	Phase 2	Multiple Myeloma
Venetoclax	Phase 3	Mantle-Cell Lymphoma
PCI-27483	Phase 2	Pancreatic Cancer
MGd	Phase 3	Metastatic Cancer
Gemcitabine	Phase 3	Metastatic Pancreatic Adenocarcinoma
PCI-32765	Phase 2	B-cell Chronic Lymphocytic Leukemia
Next-line ibrutinib	Phase 3	Chronic Lymphocytic Leukemia
Ibrutinib	Phase 3	Diffuse Large B Cell Lymphoma Relapsed
Carfilzomib	Phase 2	Multiple Myeloma
ofatumumab	Phase 3	B-cell Chronic Lymphocytic Leukemia

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for PCYC (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.